Direttore Clinica Urologica Ospedale Molinette Università degli Studi di Torino : Libri e Pubblicazioni

Treating Urothelial Bladder Cancer

Bladder cancer represents the most common genitourinary cancer in male population after prostate cancer and the most common in women, with around 80,000 estimated new cases during 2016 only in the United States.


Treating Urothelial Bladder Cancer
Bladder cancer represents the most common genitourinary cancer in male population after prostate cancer and the most common in women, with around 80,000 estimated new cases during 2016 only in the United States. It is mainly a disease of the elderly, with the majority of new diagnoses occurring in the decade between 75 and 84 years. Therefore, with the aging of population, bladder cancer will become even more frequent and develop in an even bigger public health challenge in the near future. This will lead to a mandatory multidisciplinary management, which will call in not only the urologist, medical oncologist, and radiotherapist but also the general practitioner, geriatrician, and public health manager.

Moreover, after many years, novel technologies and new therapeutic agents are becoming a reality in the treatment of urothelial bladder cancer, carrying the opportunity to change the natural history of the disease. This will lead, as already happens for other cancers, to more and more individualized treatments. Therefore, one of the major challenge will be the correct selection of the right treatment for the right patient. All the figures which are taking part in the management of bladder cancer will be involved in this challenging process, and, to achieve these ambitious results, they must be open to change and improve their approach to the disease.

The idea of writing a book focused on the treatments’ novelties in bladder cancer management arose after the success of the first two editions of Global Congress on Bladder Cancer. The great interest originated from the debate between all the figures involved in bladder cancer management convinced us that this would be the right time to publish a book that will be able to act as a guide in these years of change.

The dissemination of effective new diagnostic technologies and the improvement in minimally invasive radical surgery with robotic surgery along with the advent of systemic immunotherapy make the present time unique in the history of bladder cancer and open the premise for a breakthrough in disease outcome.

Are we ready for the “new era of bladder cancer”?

Torino, Italy
P. Gontero
F. Soria

Immagine 2